Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan I Vear

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Pediatric Blood & Cancer|May 18, 2013
Warfarin pharmacogenomics in childrenSusan I Vear, C Michael Stein, Richard H Ho
Annual Review of Pharmacology and Toxicology|July 9, 2019
Gene-Based Dose Optimization in ChildrenLaura B Ramsey, Jacob T Brown, Susan I Vear, et al.
British Journal of Haematology|March 8, 2014
The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric populationSusan I Vear, Gregory D Ayers, Sara L Van Driest, et al.
Pharmacogenomics|December 19, 2014
Genotype and risk of major bleeding during warfarin treatmentVivian K Kawai, Andrew Cunningham, Susan I Vear, et al.
The Pharmacogenomics Journal|November 2, 2019
CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysisMasanobu Takeuchi, Tohru Kobayashi, Tina Biss, et al.
Plos One|June 2, 2015
Genome-Wide Association Study of Serum Creatinine Levels during Vancomycin TherapySara L Van Driest, Tracy L McGregor, Digna R Velez Edwards, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Pediatric Blood & Cancer|May 18, 2013
Warfarin pharmacogenomics in childrenSusan I Vear, C Michael Stein, Richard H Ho
Annual Review of Pharmacology and Toxicology|July 9, 2019
Gene-Based Dose Optimization in ChildrenLaura B Ramsey, Jacob T Brown, Susan I Vear, et al.
British Journal of Haematology|March 8, 2014
The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric populationSusan I Vear, Gregory D Ayers, Sara L Van Driest, et al.
Pharmacogenomics|December 19, 2014
Genotype and risk of major bleeding during warfarin treatmentVivian K Kawai, Andrew Cunningham, Susan I Vear, et al.
The Pharmacogenomics Journal|November 2, 2019
CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysisMasanobu Takeuchi, Tohru Kobayashi, Tina Biss, et al.
Plos One|June 2, 2015
Genome-Wide Association Study of Serum Creatinine Levels during Vancomycin TherapySara L Van Driest, Tracy L McGregor, Digna R Velez Edwards, et al.
Pageof 1